• Tiamulin: Linking Ribosome Mechanism to PK/PD

  2026-08-15

  Tiamulin (Thiamutilin) is more than a veterinary pleuromutilin antibiotic: its ribosomal binding site, resistance biology, and PK/PD thresholds together define how it should be evaluated. This article connects molecular mechanism to assay design, animal-health translation, and emerging anti-inflammatory research.

• Human iPSC Sensory Neurons for HSV-1 Latency

  2026-08-15

  A 2025 mBio study developed a scalable protocol for differentiating human induced pluripotent stem cells into functional sensory neurons and established measurable HSV-1 latency and reactivation in this human neuronal system. The model combines neuronal excitability with virologic and chromatin-based latency criteria, creating a useful platform for studying neuron-intrinsic mechanisms that are difficult to resolve in animal models.

• BMS-777607 Workflows for MET and MK Research

  2026-08-14

  BMS-777607 provides a selective way to interrogate MET-family signaling in cancer metastasis models while offering a carefully controlled exploratory arm for stem-cell-derived megakaryocyte research. This guide connects mechanism, assay design, product handling, and troubleshooting without treating the emerging platelet application as clinically validated.

• Sulfamonomethoxine: From DHPS to Translation

  2026-08-14

  Sulfamonomethoxine is more than a veterinary antimicrobial reference compound. By connecting DHPS inhibition, exposure design, aquaculture applications, pharmacokinetic benchmarking, and environmental fate, researchers can build translational studies that distinguish target engagement from real-world performance and ecological risk.

• TBXA2R–ERM Signaling Drives TNBC Metastasis

  2026-08-13

  The reference study identifies TBXA2R as a GPCR that activates ERM proteins through Gαq/11-, Gα12/13-, Rho GTPase-, SLK-, and LOK-dependent signaling. This axis links receptor activity to triple-negative breast cancer cell motility, invasion, and metastatic colonization, providing a mechanistic framework for studying GPCR-driven cytoskeletal remodeling.

• Prednisolone at the Signaling–Degradation Interface

  2026-08-13

  Prednisolone remains a powerful synthetic glucocorticoid for dissecting receptor-driven inflammation and immune regulation. This thought-leadership guide connects rigorous glucocorticoid signaling research with the emerging ERAD-engaging chimera platform while clearly separating established evidence from forward-looking translational hypotheses.

• Direct Enzymatic Synthesis of Fatty Amines

  2026-08-12

  The reference study establishes a one-pot enzymatic cascade that converts renewable triglycerides and oils into primary fatty amines by combining lipase, carboxylic acid reductase, and transaminase activities. Its preparative demonstration with trilaurin shows the promise of replacing multistep, metal-catalyzed routes with a more selective process under comparatively mild biocatalytic conditions.

• 2-Hydroxypropyl-β-cyclodextrin Protocol Guide

  2026-08-12

  2-Hydroxypropyl-β-cyclodextrin is a water-compatible solubilizer for poorly soluble hydrophobic research compounds, particularly molecules with aromatic or phenyl groups. This guide covers practical inclusion-complex screening, solution preparation, and QC for pharmaceutical and biochemical workflows; it should not be treated as evidence for a specific dose, biological effect, or application outside solubility-focused research.

• Niclosamide: STAT3 Assay Workflows for Cancer Research

  2026-08-11

  Niclosamide supports mechanism-led cancer research by pairing STAT3 Tyr-705 inhibition with apoptosis, cell-cycle, and NF-κB readouts. This practical guide turns the compound’s solubility profile and pathway activity into reproducible workflows for prostate cancer and acute myelogenous leukemia model studies.

• Surrogate BBB Model for CNS Permeability Prediction

  2026-08-10

  Hu and colleagues developed a Transwell blood-brain barrier surrogate based on LLC-PK1-MOCK/MDR1 cells and combined permeability measurements with correction for lysosomal drug trapping. Across 41 compounds, the model correlated strongly with unbound brain distribution and provided a practical framework for separating passive diffusion, P-glycoprotein efflux, and intracellular sequestration during early CNS drug screening.

• Ultrafiltration for Circular RNA Purification

  2026-08-09

  Guillen-Cuevas and colleagues evaluated ultrafiltration as a scalable method for separating protein-encoding circular RNA from linear and nicked RNA produced during in vitro transcription and self-splicing. Polyethersulfone membranes delivered 86% purity with more than 50% yield under the reported conditions, outperforming size-exclusion HPLC on purity while offering a practical path toward larger-scale circRNA processing.

• Berberine, RXRα/PPARγ, and SASP in Atherosclerosis

  2026-08-08

  The reference study identifies an RXRα/PPARγ/NEDD4 axis through which berberine suppresses senescence-associated secretory phenotype inflammation in macrophage-derived foam cells and atherosclerotic plaques. Its combination of mouse disease modeling, foam-cell assays, Smart-seq analysis, and macrophage-specific RXRα knockdown provides a mechanistic framework for connecting nuclear-receptor activity with ubiquitin-dependent control of inflammatory aging.

• Sodium Orthovanadate in Translational Signaling

  2026-08-07

  Sodium Orthovanadate is more than a routine phosphatase inhibitor: it is a strategic control for separating true phosphorylation biology from sample-handling artifacts. This article connects Na3VO4 mechanism, assay design, metabolic signaling, and translational decision-making.

• Indazole-Based Glucagon Receptor Antagonists: Synthesis and

  2026-08-07

  This study introduces a novel series of indazole- and indole-based glucagon receptor antagonists with potent activity in models relevant to type 2 diabetes. Through innovative scaffold design and precise amide bond formation methods, the research advances the development of targeted therapies and provides methodological insights for peptide and amide chemistry.

• Foretinib (GSK1363089): Multikinase Inhibitor for Cancer Mod

  2026-08-06

  Foretinib (GSK1363089) is a potent ATP-competitive multikinase inhibitor used in cancer research for its strong and selective inhibition of VEGFR, Met, and related kinases. It exhibits nanomolar activity against tumor cell proliferation and motility in both in vitro and in vivo models, supporting its value in advanced metastasis studies. APExBIO supplies Foretinib (A2974) for research purposes, enabling reproducible cell-based workflows.

454 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page